Drugs / AI-081
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06635785 | Mar 2025 → Jun 2027 expected | neoplasm | OncoC4, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-12-02 | OncoC4, Inc. | Regulatory OncoC4 Announces FDA Clearance of IND Application for Potential Best-in-Class PD-1/VEGF Bispecific AI-081 in Advanced Solid Tumors oncoc4.com ↗ |
All press releases naming this drug 2 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AI-081 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06635785 ↗ |
| Modality | Monoclonal antibody | “humanized monoclonal antibody” NCT06635785 ↗ |
| Route | Intravenous | “AI-081 will be given by IV infusion in designated dose, q3w.” NCT06635785 ↗ |